HAYWARD, Calif.--(BUSINESS WIRE)--IMPAX Laboratories, Inc. (OTC: IPXL), through its generic drug division Global Pharmaceuticals, announced that yesterday the U.S. Food and Drug Administration (FDA) granted final approval of the Company’s Abbreviated New Drug Application (ANDA) for a generic version of Prilosec 40 mg Delayed-release Capsules. AstraZeneca markets Prilosec for the treatment of duodenal/gastric ulcers and GERD (gastro-esophageal reflux disease).
